New therapies target the toxic consequences of cholestatic liver disease

Area of Science:

• Hepatology
• Pharmacology
• Gastroenterology

Background:

• Cholestatic liver diseases often stem from biliary tree lesions, leading to secondary bile salt toxicity.
• Current therapies focus on mitigating this secondary injury, with some agents showing promise in preclinical studies.

Purpose of the Study:

• To review pharmaceuticals that modulate bile salt signaling for treating chronic cholestatic liver diseases in humans.
• To evaluate the potential of novel therapeutic targets in managing these conditions.

Main Methods:

• Review of existing literature on pharmaceuticals targeting bile salt signaling pathways.
• Analysis of preclinical and clinical trial data for agents like FXR- and PPAR-agonists, ASBT-inhibitors, and nor-UDCA.

Main Results:

• Several drug classes, including nuclear hormone receptor agonists and bile salt transporter inhibitors, demonstrate positive effects on biochemical endpoints.
• Preclinical data suggest efficacy for agents in treating primary sclerosing cholangitis.

Conclusions:

• Nuclear hormone receptors and bile salt transport proteins are viable targets for novel cholestatic liver disease therapies.
• While biochemical improvements are observed, long-term data on histological outcomes and survival are required. Symptomatic relief remains an area for further investigation.